26 withdrawn, 18 completed, 18 terminated, 12 active not recruiting. 59 Phase 2, 53 Phase 1, 8 Phase 3.
Follow ImmunityBio, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| N-803 in Combination With Pembrolizumab and Enfortumab Vedotin for Treatment of Urothelial Cancer Nogapendekin Alfa Inbakicept (NAI), enfortumab vedotin (EV), Pembrolizumab - Metastatic Urothelial Carcinoma, Urothelial Carcinoma | Phase 1 | Not yet recruiting | ImmunityBio, Inc. | 18 | 2026-12-01 | 2026-09-24 |
| Sipuleucel-T (Sip-T) in Combination With N-803 in Metastatic Androgen Pathway Modulation Resistant (mAPMR) Prostate Cancer Sipuleucel-T, N803 - Prostate Cancer, Metastatic Prostate Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 30 | 2026-11-30 | 2026-08-10 |
| NAI Plus Standard of Care Compared With Placebo Plus Standard of Care in Critically Ill Adults With Sepsis Nogapendekin alfa inbakicept (NAI), Placebo - Sepsis | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 50 | 2026-10-15 | 2026-09-25 |
| Open-Label, Phase 1 Clinical Trial of Neoadjuvant Nogapendekin Alfa Inbakicept, Sotevtamab, and Zabadinostat in Combination With Gemcitabine and Nab-Paclitaxel for Participants With Borderline Resectable or Locally Advanced Pancreatic Cancer Nogapendekin Alfa Inbakicept (N803), Sotevtamab, Zabadinostat (CXD101) - Pancreatic Cancer Resectable, Pancreatic Cancer | Phase 1 | Withdrawn | ImmunityBio, Inc. | 2026-09-01 | 2026-08-28 | |
| Phase 2 Study of NAI, HPV Vaccine, and Nab-Paclitaxel in HPV-Positive Oropharyngeal Cancer Followed by De-Intensified Radiation Compared With Standard Chemoradiation Nogapendekin Alfa Inbakicept (NAI), hAd5-HPV Vaccine (IBRX-042), Nab-Paclitaxel - HPV-Positive Oropharyngeal Squamous Cell Carcinoma, Oropharyngeal Squamous Cell Carcinoma | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 70 | 2026-07-22 | 2026-06-04 |
| First-Line Ipilimumab Plus Nivolumab and Nogapendekin Alfa Inbakicept (N-803) in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer Ipilimumab, Nivolumab, Nogapendekin alfa inbakicept - Non-small Cell Lung Cancer Stage IV, Non-small Cell Lung Cancer Recurrent | Phase 1 / Phase 2 | Recruiting | Washington University School of Medicine | 26 | 2026-07-07 | 2026-07-10 |
| NAI for Sepsis With Persistent Lymphopenia Nogapendekin alfa inbakicept (NAI), Standard of Care (SOC) - Sepsis, Septic Shock | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 50 | 2026-07-06 | 2026-05-11 |
| Phase 3 Study of Nogapendekin Alfa Inbakicept Plus Standard of Care vs Standard of Care in First-Line Advanced or Metastatic NSCLC Drug: Nogapendekin alfa inbakicept (NAI), Pembrolizumab, Cisplatin or Carboplatin - NSCLC (Advanced Non-small Cell Lung Cancer), Metastatic NSCLC | Phase 3 | Withdrawn | ImmunityBio, Inc. | 2026-05-29 | 2026-06-22 | |
| ANKTIVA Plus BCG Versus BCG Monotherapy In Participants With BCG-Naïve/BCG-Exposed High-Grade Non-Muscle Invasive Papillary Bladder Cancer BCG (50 mg) plus ANKTIVA (400 µg), BCG (50 mg) - NMIBC | Phase 3 | Withdrawn | ImmunityBio, Inc. | 2026-05-15 | 2026-05-19 | |
| Study of Nogapendekin Alfa Inbakicept and iNKT Cells in Critically Ill Adults With Severe Community-Acquired Pneumonia Nogapendekin alfa inbakicept (NAI), agenT-797 - Community-Acquired Pneumonia (CAP), Acute Respiratory Distress Syndrome (ARDS) | Phase 3 | Withdrawn | ImmunityBio, Inc. | 2026-04-15 | 2026-05-08 | |
| Nogapendekin Alfa-Inbakicept and iNKT Cells for Critically Ill Adults With Severe Community-Acquired Pneumonia (With or Without Sepsis/ARDS) Nogapendekin Alfa-Inbakicept (NAI), Allogeneic invariant Natural Killer T (iNKT) Cells (AgenT-797) - Acute Respiratory Distress Syndrome, Severe Community-Acquired Pneum | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2026-04-15 | 2026-05-08 | |
| Study of CD19 t-haNK and NAI With Rituximab in Participants With Indolent Non-Hodgkin Lymphoma CD19 t-haNK- IV Administration, N-803, rituximab - Relapsed B-Cell Non-Hodgkin Lymphoma | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 20 | 2026-04-01 | 2026-03-17 |
| N-803 Maintenance Therapy Post CAR T-cell Therapy in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphomas N803 - B-cell Non Hodgkin Lymphoma | Phase 1 | Withdrawn | University of Utah | 2026-02-01 | 2026-04-01 | |
| Immunotherapy Before and After Surgery N-803, ETBX-071, M-CENK - High-risk Prostate Cancer | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2025-12-15 | 2026-05-05 | |
| Immunotherapy With N 803, ETBX-071, and M-CENK in Combination With Radiation for Participants With High-Risk Prostate Cancer. N-803 (IL-15 Superagonist), ETBX-071 (PSA-based Oncolytic Virus), M-CENK (Activated NK Cells) - High-risk Prostate Cancer | Phase 2 | Withdrawn | ImmunityBio, Inc. | 2025-12-01 | 2026-05-05 | |
| A Study to Assess Anktiva in Patients With Long Covid-19. N-803 (IL-15 Superagonist) - Long COVID | Phase 2 | Recruiting | ImmunityBio, Inc. | 20 | 2025-11-14 | 2026-05-11 |
| Study of Relapsed/ Refractory B-cell Non- Hodgkin Lymphoma CD19 t-haNK- IV Administration - Relapsed B-Cell Non Hodgkin Lymphoma | Phase 2 | Recruiting | ImmunityBio, Inc. | 20 | 2025-11-11 | 2026-05-04 |
| Clinical Trial of Ablation Therapy in Participants With Intermediate-Risk Non-Muscle Invasive Papillary Bladder Cancer N-803 and BCG, N-803 and Gemcitabine - Non-muscle Invasive Bladder Cancer (NMIBC) | Phase 2 | Not yet recruiting | ImmunityBio, Inc. | 20 | 2025-11-01 | 2025-10-16 |
| ResQ133A-NMIBC: Intravesical Recombinant Mycobacterium (rMBCG) in Participants With NMIBC Eligible to Receive Intravesical Tice BCG Intravesical Recombinant Mycobacterium (rMBCG) - NMIBC | Phase 1 / Phase 2 | Recruiting | ImmunityBio, Inc. | 40 | 2025-10-15 | 2026-03-27 |
| Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants With Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint In N-803, Tislelizumab, Docetaxel - NSCLC Stage IV | Phase 3 | Recruiting | ImmunityBio, Inc. | 507 | 2025-10-01 | 2026-07-27 |
Showing 20 of 92. Sign in to see all of them.
COVID-19 (9) · Carcinoma, Non-Small-Cell Lung (8) · Non-Muscle Invasive Bladder Neoplasms (8) · Pancreatic Neoplasms (8) · Neoplasm Metastasis (6) · Carcinoma, Transitional Cell (5) · Carcinoma, Merkel Cell (4) · Lymphoma, B-Cell (4) · Lymphopenia (4) · Sarcoma (4) · Sepsis (4) · Squamous Cell Carcinoma of Head and Neck (4) · Urinary Bladder Neoplasms (4) · Colorectal Neoplasms (3) · Critical Illness (3)
ALT-803 (56) · Cyclophosphamide (25) · avelumab (23) · 130-nm albumin-bound paclitaxel (22) · Fluorouracil (21) · Leucovorin (20) · Bevacizumab (18) · Capecitabine (18) · yeast-CEA vaccine (13) · Cisplatin (12) · Omacor (11) · DOXO-EMCH (10) · Oxaliplatin (10) · Gemcitabine (9) · Radiosurgery (9)
United States (63) · South Africa (6) · Hungary (3) · Australia (2) · Canada (2) · India (2) · Russia (2) · Spain (2) · Chile (1) · Denmark (1) · France (1) · Israel (1) · Italy (1) · Netherlands (1) · Poland (1)
Bobby Reddy, MD (5) · Leonard Sender, MD (3) · Amanda Cashen, M.D. (2) · Bruce Brown (2) · Dan Levitt, M.D. (2) · Dan Levitt, MD (2) · Jayson Garmizo (2) · Sant Chawla, M.D. (2) · Daniel Levitt, M.D., Ph.D. (1) · Daniel Levitt, MD, PhD (1) · Daniel Morgensztern, M.D. (1) · Daniel Von Hoff, MD, FACP (1) · Giordano Fabricio Cittolin Santos, MD, PhD (1) · Karim Chamie, MD (1) · Lennie Sender, MD (1)
PMID 38953850, PMID 26378637, PMID 34797911, PMID 35196021, PMID 40956664
F32CA200253 (1), P50CA171963 (1)